• Werewolf Therapeutics director Luke Evnin reported sales totaling 100,581 common shares on May 5-7 under a Rule 10b5-1 trading plan.
• Sales were priced at weighted-average prices of USD 0.69, USD 0.66, USD 0.63 across the three sessions.
• Indirect beneficial ownership fell to 1,578,749 shares following the May 7 transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001134657-26-000009), on May 07, 2026, and is solely responsible for the information contained therein.